您现在的位置: 首页  > 学术信息  > 正文

【院长论坛】PRDM1/Blimp-1 as a Tumor Suppressor Gene in Lymphoid Malignancies

发布日期:2012-11-07    浏览次数:

  报告人: Wayne Tam, M.D., Ph.D.

  Associate Professor

  Division of Hematopathology

  Department of Pathology & Laboratory Medicine

  Joan & Sanford Weill Medical College of Cornell University

时间:2012年11月9日(星期五)上午10:00 - 11:30

地点:北京大学医学部病理楼二层中厅

主持人:张波 教授

报告人简介:

  Dr. Wayne Tam received his undergraduate education at the Johns Hopkins University with honors and subsequently graduated from the Cornell-Rockefeller-Memorial Sloan-Kettering Tri-Institutional combined MD and PhD program. Dr. Wayne Tam is an academic hematopathologist in the Division of Hematopathology of the Department of Pathology and Laboratory Medicine at Weill Cornell Medical Center, with expertise in bone marrow and lymph node pathology, flow cytometry, immunohistochemistry and molecular hematopathology.  Besides practising clinical hematopathology in an internationally renowned hematopathology group, Dr. Tam also directs a funded translational research program which aims at understanding the pathogenesis of leukemias and lymphomas and identifying biomarkers with implications in diagnosis and prognosis of these cancers.  His research focuses on the role of microRNAs and tumor suppressor genes in hematopoietic malignancies.  He has actively published in peer-reviewed journals in these areas and is a recognized expert in microRNAs and cancer.  He has been an invited speaker in several national and international conferences.  Dr. Tam serves as an Editorial Board Member of Molecular Medicine Reports and is an ad hoc reviewer for more than 10 peer-reviewed journals, including Blood, Clinical Cancer Research, Human Pathology, Laboratory Investigation, and Journal of Biological Chemistry.  He is currently a member of the Translational Research Committee of the Department and the Director of the Tumor Bank in the Division of Hematopathology.  He is also the case review pathologist of the AIDS Malignanices Clinical Trial Consortium.  He recently received the Eminent Scientist of the Year Award in Cancer Research and Gene Biology by the International Research Promotion Council.  Dr. Tam's ultimate goal is to integrate his clinical and research expertise to facilitate discovery of novel target therapy for the benefit of patients with lymphomas and leukemias.